A thirty-three-year-old female with acute intermittent porphyria (A.I.P.) was having regular attacks of the disease with her menstrual periods. During several of these attacks she received intravenous haematin, which was followed by chemical and clinical remissions. Hormones failed to prevent the regular attacks, which were completely prevented by 200 mg of haematin, given approximately once a week for six months. There were no changes in menstruation. The monthly attacks recurred on withdrawal of haematin.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0140-6736(78)92217-1DOI Listing

Publication Analysis

Top Keywords

intravenous haematin
8
regular attacks
8
attacks
5
prevention acute
4
acute porphyric
4
porphyric attacks
4
attacks intravenous
4
haematin
4
haematin thirty-three-year-old
4
thirty-three-year-old female
4

Similar Publications

Acute intermittent porphyria (AIP) is a rare inherited metabolic disorder caused by decreased activity of the enzyme porphobilinogen deaminase in the heme synthesis pathway. This leads to the accumulation of toxic porphyrin precursors, such as porphobilinogen and δ-aminolevulinic acid. Clinical manifestations typically include episodic bouts of severe neurovisceral pain and autonomic dysfunction.

View Article and Find Full Text PDF

Therapeutic approach to acute crises of hepatic porphyrias.

Rev Clin Esp (Barc)

December 2024

Unidad de Enfermedades Raras y Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Article Synopsis
  • - Acute hepatic porphyria is a genetic disorder that affects the production of heme and is primarily caused by issues with specific enzymes, with acute intermittent porphyria being the most common type.
  • - Triggered by factors that induce the enzyme ALA synthase 1, this disorder leads to the buildup of toxic heme intermediates, causing severe symptoms such as abdominal pain, muscle weakness, and autonomic dysfunction; women are more prone to these attacks than men.
  • - Prompt recognition and treatment are essential, requiring urgent medical interventions like intravenous opioids and glucose, while preventive measures include hormone suppression and possibly liver transplantation.
View Article and Find Full Text PDF

Mesenchymal stem cell-derived extracellular vesicles mitigate neuronal damage from intracerebral hemorrhage by modulating ferroptosis.

Stem Cell Res Ther

August 2024

Department of Neurosurgery, Xi'an Central Hospital, Xi'an Jiaotong University, No. 161, West 5th Road, Xincheng District, Xi'an, 710003, P.R. China.

Background: Hemorrhagic stroke is a devastating cerebrovascular event with a high rate of early mortality and long-term disability. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) for neurological conditions, such as intracerebral hemorrhage (ICH), has garnered considerable interest, has garnered considerable interest, though their mechanisms of action remain poorly understood.

Methods: EVs were isolated from human umbilical cord MSCs, and SPECT/CT was used to track the Tc-labeled EVs in a mouse model of ICH.

View Article and Find Full Text PDF

Platelet Membrane-Coated Curcumin-PLGA Nanoparticles Promote Astrocyte-Neuron Transdifferentiation for Intracerebral Hemorrhage Treatment.

Small

October 2024

School of Pharmacy, Jiangsu University, The International Institute on Natural Products and Stem Cells (iNPS), Key Lab for Drug Delivery & Tissue Regeneration, Jiangsu Provincial Research Center for Medicinal Function Development of New Food Resources, Zhenjiang, 202013, China.

Intracerebral hemorrhage (ICH) is a hemorrhagic disease with high mortality and disability rates. Curcumin is a promising drug for ICH treatment due to its multiple biological activities, but its application is limited by its poor watersolubility and instability. Herein, platelet membrane-coated curcumin polylactic-co-glycolic acid (PLGA) nanoparticles (PCNPs) are prepared to achieve significantly improved solubility, stability, and sustained release of curcumin.

View Article and Find Full Text PDF
Article Synopsis
  • The acute hepatic porphyrias (AHPs) are a group of four rare genetic disorders that cause serious, episodic neurological symptoms due to a buildup of specific chemical precursors in the liver.
  • Diagnosis can be challenging due to non-specific symptoms, but specialized tests during attacks can confirm the condition.
  • Treatment for severe episodes includes intravenous hemin, and potential long-term management with givosiran is available for patients with frequent attacks; regular health surveillance is also necessary to monitor for serious complications.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!